艾锐威特生物制药
AVBP
16.66
-0.13
-0.77%
艾锐威特生物制药
US · AVBP
#3057 按市值排名
上市于 2024
16.66
-0.13
-0.77%
实时 - 追踪5344个代码 - 心跳于452秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了2.5个百分点。
机构持股
- 机构持股比例
- 103.13% -2.51pp
- 机构数量
- 193 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund37.61%
Hedge Fund31.81%
Mutual Fund29.61%
Public Company2.49%
Individual/Insider1.82%
Private Company1.39%
Government Pension Fund0.18%
主要股东 截至 2026-06-30
Montanova Capital, LLC
9.16% · 4.52M 股
Infinitum Asset Management, LLC
9.00% · 4.44M 股
Hillhouse Capital Management, Ltd.
7.97% · 3.93M 股
BlackRock
6.59% · 3.25M 股
OrbiMed Advisors LLC
6.14% · 3.03M 股
FMR
5.64% · 2.78M 股
HBM Healthcare Investments AG
4.45% · 2.20M 股
Eli Lilly Investment Consulting (Shanghai) Co., Ltd.
4.15% · 2.05M 股
Vanguard Capital Management, LLC
4.13% · 2.03M 股
Octagon Capital Advisors LP
4.00% · 1.97M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪47份申报 · 29次买入 · 1次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Robin LaChapelle | Co-Founder & COO | 1.08% |
| Zhengbin Yao | Chairperson & CEO | 0.44% |
| Stuart Lutzker | Co-Founder, President of Research & Development and Director | 0.30% |
| Kristine Peterson | Director | -- |
| Hillhouse Capital Management, Ltd. | -- | -- |
| Merdad Parsey | Independent Director | -- |
| John Hohneker | Director | -- |
| Winston Kung | Chief Financial Officer | -- |
| Christian Nolet | Independent Director | -- |
| James Kastenmayer | General Counsel | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-17 | Kristine Peterson | Director | Other Derivative Acquisition | +13,562 | $31.74 |
| 2026-06-17 | Merdad Parsey | Independent Director | Other Derivative Acquisition | +13,562 | $31.74 |
| 2026-06-17 | John Hohneker | Director | Other Derivative Acquisition | +13,562 | $31.74 |
| 2026-06-17 | Christian Nolet | Independent Director | Other Derivative Acquisition | +13,562 | $31.74 |
| 2026-02-01 | Zhengbin Yao | Chairperson & CEO | Other Derivative Acquisition | +550,000 | $22.67 |
| 2026-02-01 | Robin LaChapelle | Co-Founder & COO | Other Derivative Acquisition | +130,000 | $22.67 |
| 2026-02-01 | Stuart Lutzker | Co-Founder, President of Research & Development and Director | Other Derivative Acquisition | +150,000 | $22.67 |
| 2026-02-01 | Winston Kung | Chief Financial Officer | Other Derivative Acquisition | +140,000 | $22.67 |
| 2026-02-01 | James Kastenmayer | General Counsel | Other Derivative Acquisition | +130,000 | $22.67 |
| 2025-12-09 | Hillhouse Capital Management, Ltd. | -- | Open Market Disposition | -555,555 | $23.37 |
| 2025-07-10 | Robin LaChapelle | Co-Founder & COO | Derivative Exercise and Retained | +11,153 | $2.28 |
| 2025-06-17 | Kristine Peterson | Director | Other Derivative Acquisition | +15,502 | $24.89 |
| 2025-06-17 | Merdad Parsey | Independent Director | Other Derivative Acquisition | +15,502 | $24.89 |
| 2025-06-17 | John Hohneker | Director | Other Derivative Acquisition | +15,502 | $24.89 |
| 2025-06-17 | Christian Nolet | Independent Director | Other Derivative Acquisition | +15,502 | $24.89 |
| 2025-04-27 | Merdad Parsey | Independent Director | Other Derivative Acquisition | +28,346 | $20.92 |
| 2025-02-02 | Zhengbin Yao | Chairperson & CEO | Other Derivative Acquisition | +380,000 | $27.56 |
| 2025-02-02 | Robin LaChapelle | Co-Founder & COO | Other Derivative Acquisition | +120,000 | $27.56 |
| 2025-02-02 | Stuart Lutzker | Co-Founder, President of Research & Development and Director | Other Derivative Acquisition | +120,000 | $27.56 |
| 2025-02-02 | Winston Kung | Chief Financial Officer | Other Derivative Acquisition | +120,000 | $27.56 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
艾锐威特生物制药 讨论区 0 条评论